Eva K Fenwick1,2, Chui Ming Gemmy Cheung2,3, Peng Guan Ong2, Gavin Tan2,3, Shu Yen Lee2,3, Ian Yeo2,3, Ching Yu Cheng2,3, Tien Y Wong1,2,3, Ecosse L Lamoureux1,2,3. 1. Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, Victoria, Australia. 2. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore. 3. Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Abstract
AIMS: To determine the impact of neovascular age-related macular degeneration (nAMD) on vision-related quality of life (VRQoL) in an Asian population. METHODS: In this cross-sectional study, 162 subjects with nAMD from the Asian AMD Phenotyping Study and 105 randomly sampled age-matched and gender-matched controls from the population-based Singapore Chinese Eye Study were recruited. nAMD was categorised as either polypoidal choroidal vasculopathy (PCV) or 'typical' AMD (tAMD). The reading, mobility and emotional well-being subscales of the impact of vision impairment (IVI) scale were validated using Rasch analysis and used as the main outcome measures and collectively referred to as VRQoL. Multivariate linear regression analyses were performed to assess the impact of nAMD overall, and PCV and tAMD subtypes, on the three IVI domains. RESULTS: Of the 162 with nAMD, 103 (63.6%) had PCV and 59 (36.4%) had tAMD. In multivariate models, nAMD overall was independently associated with a 21% reduction in reading (β=-1.08; CI -1.58 to -0.57); 16% reduction in mobility (β=-0.74; -1.14 to -0.33) and 44% reduction in emotional well-being (β=-2.15; -2.83 to -1.47) compared with controls. There were significant VRQoL deficits (p<0.05) associated with both PCV and tAMD; these deficits were similar and not statistically different between the two nAMD subtypes (p>0.05). CONCLUSIONS: Neovascular AMD, including both PCV and tAMD subtypes, has a detrimental impact on VRQoL in Asian subjects independent of level of vision impairment. Interventions to increase reading capacity, enhance mobility and independence and improve mental health outcomes for subjects with neovascular AMD further address the impact of the condition on VRQoL in addition to pharmacological therapies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
AIMS: To determine the impact of neovascular age-related macular degeneration (nAMD) on vision-related quality of life (VRQoL) in an Asian population. METHODS: In this cross-sectional study, 162 subjects with nAMD from the Asian AMD Phenotyping Study and 105 randomly sampled age-matched and gender-matched controls from the population-based Singapore Chinese Eye Study were recruited. nAMD was categorised as either polypoidal choroidal vasculopathy (PCV) or 'typical' AMD (tAMD). The reading, mobility and emotional well-being subscales of the impact of vision impairment (IVI) scale were validated using Rasch analysis and used as the main outcome measures and collectively referred to as VRQoL. Multivariate linear regression analyses were performed to assess the impact of nAMD overall, and PCV and tAMD subtypes, on the three IVI domains. RESULTS: Of the 162 with nAMD, 103 (63.6%) had PCV and 59 (36.4%) had tAMD. In multivariate models, nAMD overall was independently associated with a 21% reduction in reading (β=-1.08; CI -1.58 to -0.57); 16% reduction in mobility (β=-0.74; -1.14 to -0.33) and 44% reduction in emotional well-being (β=-2.15; -2.83 to -1.47) compared with controls. There were significant VRQoL deficits (p<0.05) associated with both PCV and tAMD; these deficits were similar and not statistically different between the two nAMD subtypes (p>0.05). CONCLUSIONS:Neovascular AMD, including both PCV and tAMD subtypes, has a detrimental impact on VRQoL in Asian subjects independent of level of vision impairment. Interventions to increase reading capacity, enhance mobility and independence and improve mental health outcomes for subjects with neovascular AMD further address the impact of the condition on VRQoL in addition to pharmacological therapies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Degeneration; Macula; Public health; Vision
Authors: Eva K Fenwick; Ryan E K Man; Chui Ming Gemmy Cheung; Charumathi Sabanayagam; Ching-Yu Cheng; Kumari Neelam; Jacqueline Chua; Alfred T L Gan; Paul Mitchell; Tien Y Wong; Ecosse L Lamoureux Journal: JAMA Ophthalmol Date: 2017-05-01 Impact factor: 7.389
Authors: Preeti Gupta; Eva K Fenwick; Ryan E K Man; Alfred T L Gan; Charumathi Sabanayagam; Debra Quek; Chaoxu Qian; Chui Ming Gemmy Cheung; Ching-Yu Cheng; Ecosse L Lamoureux Journal: Sci Rep Date: 2022-05-19 Impact factor: 4.996
Authors: Chui Ming Gemmy Cheung; Alfred Gan; Qiao Fan; Miao Ling Chee; Rajendra S Apte; Chiea Chuen Khor; Ian Yeo; Ranjana Mathur; Ching-Yu Cheng; Tien Yin Wong; E Shyong Tai Journal: J Lipid Res Date: 2017-07-11 Impact factor: 5.922
Authors: Rituparna Ghoshal; Sharanjeet Sharanjeet-Kaur; Norliza Mohamad Fadzil; Somnath Ghosh; Nor Fariza Ngah; Roslin Azni Abd Aziz Journal: Int J Environ Res Public Health Date: 2020-09-02 Impact factor: 3.390
Authors: Vincent Daien; Robert P Finger; James S Talks; Paul Mitchell; Tien Y Wong; Taiji Sakamoto; Bora M Eldem; Jean-François Korobelnik Journal: Br J Ophthalmol Date: 2020-10-31 Impact factor: 4.638
Authors: Myra B McGuinness; Robert P Finger; Zhichao Wu; Chi D Luu; Fred K Chen; Jenifer J Arnold; Usha Chakravarthy; Wilson J Heriot; Jim Runciman; Robyn H Guymer Journal: Transl Vis Sci Technol Date: 2019-09-11 Impact factor: 3.283